Preventing Perinatal Hepatitis B Transmission

Perinatal hepatitis B transmission occurs when hepatitis B virus passes from a pregnant person to their baby, most often during labour and birth. Without timely prevention, an infected newborn has a high risk of developing chronic hepatitis B, which can later cause cirrhosis, liver failure or hepatocellular carcinoma. The good news is that transmission can usually be prevented through antenatal screening, newborn vaccination and, when indicated, hepatitis B immunoglobulin.

The prevention plan has two connected parts. The first is active immunisation with hepatitis B vaccine, which teaches the infant’s immune system to recognise the virus. The second is passive protection with hepatitis B immunoglobulin, or HBIG, which supplies ready-made antibodies while the vaccine response develops. Correct timing matters as much as the products themselves.

This topic remains especially relevant in Australia, where families may have links to regions with higher hepatitis B prevalence across Asia and the Pacific. A patient receiving antenatal care in Sydney, Melbourne, Brisbane or Darwin may need coordinated support between a GP, midwife, obstetrician, infectious diseases specialist, maternity hospital and public health service.

Why Vertical Transmission Matters

Hepatitis B can be acquired through sexual contact, blood exposure or transmission from an infected parent to a baby. In the perinatal setting, exposure commonly happens around delivery when the newborn contacts infected blood or body fluids. The risk is substantially higher when the pregnant person has a high hepatitis B viral load or is hepatitis B e antigen positive.

Adult hepatitis B infection is often cleared, but infants are much more likely to develop chronic infection. An infant who becomes infected may appear well for many years while the virus continues to damage the liver. This makes prevention at birth a major public health measure rather than a response reserved for visibly unwell babies.

Antenatal screening usually begins with hepatitis B surface antigen, or HBsAg. A positive result indicates current infection and should prompt confirmation, liver assessment and testing such as hepatitis B e antigen and quantitative HBV DNA. Results also guide the newborn plan and may identify whether maternal antiviral treatment should be discussed.

The prevention principles sit within the wider field of mother-to-child infection control. Guidance on maternal HIV prevention is relevant because HIV, hepatitis B and other infections all require early testing, clear documentation and communication between maternity teams.

How Immune Prophylaxis Works

HBIG provides immediate, short-term antibody protection against hepatitis B. It is especially valuable when the newborn has been exposed to a high viral burden and has not yet developed an immune response to vaccination. HBIG and the first hepatitis B vaccine dose should be given as soon as possible after birth, ideally within 12 hours.

The injections should be administered at separate anatomical sites, such as different thighs. This avoids interference and ensures that the passive antibody preparation is not placed directly beside the vaccine. The exact HBIG dose depends on the product and local protocol, so hospital staff should follow the Australian Immunisation Handbook and the product information.

The vaccine creates active immunity. A birth dose begins the process, while later doses strengthen and maintain protection. In a baby born to a person with chronic hepatitis B, vaccine and HBIG together are considerably more effective than either intervention alone. Protection is strongest when administration is documented before discharge from the birth facility.

A high maternal HBV DNA level can increase the chance of breakthrough infection even when the infant receives appropriate prophylaxis. For this reason, specialist teams may recommend tenofovir during late pregnancy, often from around 28–32 weeks until delivery, when the viral load is high. This decision requires an individual review of renal health, liver status, pregnancy timing and local clinical guidance.

Building A Safe Vaccine Schedule

For an exposed newborn, the first step is a monovalent hepatitis B vaccine at birth, alongside HBIG when indicated. Later doses are generally given at approximately two, four and six months of age, often through combination infant vaccines included in Australia’s National Immunisation Program. The birth dose should still be recorded separately, even if later combination products contain hepatitis B antigen.

Timing can vary slightly according to the vaccine brand, the infant’s gestational age, birth weight and the state or territory schedule. Very premature or low-birth-weight infants may need a specialist plan because their initial immune response can be less predictable. A delayed dose should be given as soon as practical rather than restarting the entire series.

Parents may hear different advice from a hospital, GP clinic or community immunisation service. The answer should be checked against the child’s written record and the current Australian Immunisation Handbook, rather than relying on memory or informal online advice. In Australia, Medicare-linked general practices commonly review immunisations during the six-week, four-month and six-month baby checks.

Breastfeeding is generally safe when the newborn receives recommended prophylaxis. Hepatitis B infection is not a reason to avoid breastfeeding, and breastfeeding has important nutritional and developmental benefits. If nipples are cracked and bleeding, temporary clinical advice may be appropriate until they heal, especially where other blood exposure is possible.

Australian Testing And Care Pathway

In Australia, antenatal hepatitis B testing is routinely incorporated into pregnancy care. A positive result should be clearly entered into the maternity record and communicated to the delivery hospital before labour. This is particularly important when a family transfers from a private obstetrician to a public maternity unit or relocates between cities such as Perth and Melbourne during pregnancy.

A pregnant person with chronic hepatitis B should have liver function assessment and an HBV DNA result when available. An obstetrician or infectious diseases or hepatology specialist can assess whether antiviral therapy is appropriate and arrange long-term follow-up after birth. Treatment decisions should not focus only on preventing transmission; the parent’s own liver health remains central.

Hepatitis B is a notifiable disease in Australia, with reporting managed under state and territory public health legislation and national surveillance arrangements. Notification supports contact tracing, vaccination and access to care, but it should be handled sensitively. Clinicians should explain what information is collected, protect confidentiality and use professional interpreters when language barriers affect consent or understanding.

Access is not uniform across the country. A family in central Queensland, regional New South Wales or the Northern Territory may need extra planning for pathology, specialist appointments and timely delivery prophylaxis. Public hospitals, Aboriginal Community Controlled Health Services, outreach teams and telehealth can help coordinate care when travel to a tertiary centre is difficult.

Managing Special Situations And Follow-Up

If the mother’s hepatitis B status is unknown when labour begins, the newborn should not wait for a delayed result before receiving appropriate vaccination. The hospital should obtain urgent maternal testing and follow the newborn protocol for an infant whose mother may be infected. Clear escalation pathways help prevent missed prophylaxis during a busy overnight delivery.

When the mother is known to be HBsAg positive, staff should verify four details: the time of birth, the time and site of the vaccine, the time and site of HBIG, and the planned follow-up doses. These details belong in the child health record and discharge summary. A verbal handover alone is unreliable, especially when families move between hospitals or use different GP practices.

Post-vaccination serological testing is important for an exposed infant. Testing is commonly arranged at 9–12 months of age, or at least one to two months after the final vaccine dose, depending on the local protocol. HBsAg shows whether infection is present, while anti-HBs indicates the level of vaccine-induced protection. Testing too early can produce confusing results because of passive antibodies.

An infant with a positive HBsAg result needs specialist assessment. An infant with inadequate anti-HBs may need additional vaccination or other management based on the complete history and test results. Families should continue routine appointments even when the baby looks healthy, because chronic hepatitis B often has no early symptoms.

Comparing Prevention Approaches

The following comparison shows how each measure contributes to reducing transmission. They are complementary steps, not interchangeable alternatives.

Hospitals should treat the birth dose as time-critical, while primary care teams should protect the later appointments from becoming lost among routine baby care. Pharmacies in Australian cities often provide adult vaccination services, but newborn prophylaxis and infant schedule decisions should be coordinated through the maternity hospital, GP or immunisation clinic.

The FAOPS 2020 congress site reflects the wider perinatal medicine setting in which these issues are discussed: prevention depends on evidence, organised clinical systems and collaboration across specialties. Although the planned Tokyo meeting was cancelled in 2020, the clinical priority remains current for maternity and neonatal services.

Every pregnancy with hepatitis B should have a documented plan before delivery: maternal assessment, a newborn vaccine order, HBIG access where indicated, follow-up appointments and post-vaccination testing. Families can support this process by keeping the child health record, asking for written vaccination dates and attending the recommended GP or community immunisation visits. Clinicians should act early, communicate across services and use current Australian guidance so that a preventable infection does not become a lifelong diagnosis.